Mr. Mark Quick reports

CONAVI MEDICAL CORP. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES AND/OR PRE-FUNDED WARRANTS

Conavi Medical Corp. has set the pricing and terms of its previously announced public offering. The offering is of common shares of the company and/or prefinanced common share purchase warrants of the company in lieu of common shares.

The offering is being conducted on a commercially reasonable efforts agency basis for the issuance of a minimum of 50 million securities and a maximum of 75 million securities at a price of 20 cents per common share or 19.999 cents per prefinanced warrant, for gross proceeds of between $10-million and $15-million. Each prefinanced warrant issued in lieu of a common share at the election of any purchaser entitles the holder thereof to acquire one common share at an exercise price of 0.001 cent per common share. The prefinanced warrants will not expire and may be exercised on a net or cashless basis.

The company intends to use the net proceeds from the offering to complete a limited market release in the United States. The company also intends to use the net proceeds for working capital and other general corporate purposes.

The offering is expected to be completed pursuant to the terms and conditions of an agency agreement entered into between the company and Bloom Burton Securities Inc., on behalf of a syndicate of agents.

The company is expecting to file today, on July 29, 2026, a final short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario. There will not be any sale of securities until a receipt for the final prospectus has been issued.

The offering may be completed in one or more tranches and is expected to close initially on or about Aug. 5, 2026, or such other date as may be mutually agreed to by the company and the agents. The offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange.

The company will pay to the agents a cash fee equal to 6.5 per cent of the gross proceeds raised under the offering and grant the agents compensation options equal to 6.5 per cent of the aggregate number of securities issued under the offering, provided however the agents will receive a reduced cash commission of 3.25 per cent and no compensation options in respect of securities sold to certain purchasers on a president's list to be agreed to between the company and the agents. Each compensation option shall entitle the holder to buy one common share at the same price per common share as under the offering. The compensation options shall be exercisable until that date that is 24 months following the closing date.

In addition, the securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.

Access to the final prospectus and any amendments to such documents will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The final prospectus (when filed) will be accessible on SEDAR+. Alternatively, an electronic or paper copy of the final prospectus (when filed), as well as any amendment to such documents, may be obtained without charge from Bloom Burton by e-mail at ECM@bloomburton.com, by telephone at 416-640-7585, or by providing the contact with an e-mail address or address, as applicable. The final prospectus (when filed) contains important, detailed information about the company and the offering. Prospective investors should read the final prospectus (when filed) before making an investment decision.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration.

We seek Safe Harbor.